SCHEMBL26212920

SCHEMBL26212920

CC(C)NS(=O)(=O)c1ccccc1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
MMP1 P03956 1/20 0.64
MMP2 P08253 1/20 0.64
MMP9 P14780 1/20 0.64
MMP8 P22894 1/20 0.64
MMP13 P45452 1/20 0.64
CA12 O43570 6/20 0.58
CA9 Q16790 6/20 0.58
NPSR1 Q6W5P4 3/20 0.55
KDM4E B2RXH2 1/20 0.55
F2 P00734 3/20 0.54
PRSS1 P07477 3/20 0.54
PRSS2 P07478 3/20 0.54
PRSS3 P35030 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 1/20 0.47
ALDH1A1 P00352 1/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27000244 0.85 CA12 (0.61) CA1CA2MMP1MMP2MMP9
SCHEMBL20646732 0.85 CA1 (0.45) CA1CA2MMP1MMP2MMP9
SCHEMBL2998319 0.85 CA9 (0.45) CA1CA2MMP1MMP2MMP9
SCHEMBL14397776 0.84 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL15562586 0.83 BCAT2 (0.66) KDM4ESMN1; SMN2ALDH1A1MEN1MAPT
SCHEMBL4433906 0.80 CA1 (0.70) CA1CA2MMP1MMP2MMP9
SCHEMBL8397052 0.80 CA1 (0.75) CA1CA2MMP1MMP2MMP9
SCHEMBL26213760 0.79 CA12 (0.66) CA1CA2MMP1MMP2MMP9
SCHEMBL3922319 0.78 KDM4E (0.45) CA1CA2MMP1MMP2MMP9
Hydrochloric Acid SCHEMBL11042768 0.78 CA1 (0.72) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS CA1 3083/4885CA2 1016/4885MMP1 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.